Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D609736-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,400.90 | |
D609736-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,000.90 |
Synonyms | compound 13;i-13 |
---|---|
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of death associated protein kinase 3 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (4E)-2-(4-bromo-3-methylphenyl)-4-(pyridin-3-ylmethylidene)-1,3-oxazol-5-one |
---|---|
INCHI | InChI=1S/C16H11BrN2O2/c1-10-7-12(4-5-13(10)17)15-19-14(16(20)21-15)8-11-3-2-6-18-9-11/h2-9H,1H3/b14-8+ |
InChi Key | AIDLMCGWDDGYCV-RIYZIHGNSA-N |
Canonical SMILES | O=C1OC(=N/C/1=C/c1cccnc1)c1ccc(c(c1)C)Br |
Isomeric SMILES | CC1=C(C=CC(=C1)C2=N/C(=C/C3=CN=CC=C3)/C(=O)O2)Br |
PubChem CID | 56694877 |
PubChem CID | 56694877 |
---|
Enter Lot Number to search for COA:
1. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T. (2010) Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening.. Bioorg Med Chem, 18 (7): (2728-34). [PMID:20206532] |
2. Geering B, Stoeckle C, Rozman S, Oberson K, Benarafa C, Simon HU. (2014) DAPK2 positively regulates motility of neutrophils and eosinophils in response to intermediary chemoattractants.. J Leukoc Biol, 95 (2): (293-303). [PMID:24163421] |